Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 17;11(5):E490-E496.
doi: 10.1055/a-2048-2279. eCollection 2023 May.

Low risk of new dysplastic lesions in an inflammatory bowel disease population study with dye chromoendoscopy

Beatriz Sicilia  1 , Yago González-Lama  2 , Benito Velayos  3 , Patricia Suárez  4 , Carlos Maroto-Martín  5 , Aljandro Nuñez  6 , Luis Hernández  7 , Rosa M Sáiz-Chumillas  1 , Lucia Relea  2 , Luis Fernández-Salazar  3 , Mónica Sierra-Ausín  4 , Jesús Barrio Andrés  5 , Fernando Muñoz  6 , Lara Arias García  1
Affiliations

Low risk of new dysplastic lesions in an inflammatory bowel disease population study with dye chromoendoscopy

Beatriz Sicilia et al. Endosc Int Open. .

Abstract

Background and study aims Rates of new dysplastic lesions or cancer progression after first dye chromoendoscopy in the era of high-definition endoscopy have yet to be determined. Patients and methods A multicenter, population-based, retrospective cohort study was performed in seven hospitals in Spain. Patients with inflammatory bowel disease and fully resected (R0) dysplastic colon lesions under surveillance with high-definition dye-based chromoendoscopy were sequentially enrolled between February 2011 and June 2017, with a minimum endoscopic follow-up of 36 months. The aim was to assess the incidence of developing more advanced metachronous neoplasia by analyzing possible associated risk factors. Results The study sample included 99 patients and 148 index lesions (145 low-grade dysplasia lesions and three high-grade dysplasia [HGD] lesions with a mean follow-up of 48.76 months [IQR: 36.34-67.15]). The overall incidence of new dysplastic lesions was 0.23 per 100 patient-years, 1.15 per 100 patients at 5 years and 2.29 per 100 patients at 10 years. A history of dysplasia was associated with a higher risk of developing any grade of dysplasia during follow-up ( P = 0.025), whereas left colon lesions were associated with a lower risk ( P = 0.043). The incidence of more advanced lesions at 1 year and 10 years was 1 % and 14 % respectively, with lesion size > 1 cm being a risk factor ( P = 0.041). One of the eight patients (13 %) with HGD lesions developed colorectal cancer during follow-up. Conclusions The risk of dysplasia progressing to advanced neoplasia and, specifically, the risk of new neoplastic lesions after endoscopic resection of colitis-associated dysplasia, are both very low.

PubMed Disclaimer

Conflict of interest statement

Competing interests Dra. B. Sicilia has received support for conference attendance, speaker fees, research support and consulting fees of Abbvie, FAES, Chiesi, Dr. Falk, MSD, Tillots Pharma, Khern Pharma, Janssen, Pfizer y Takeda.

Figures

Fig. 1
Fig. 1
Flowchart.
Fig. 2
Fig. 2
Overall incidence of new dysplastic lesions.
Fig. 3
Fig. 3
Probability that a new dysplastic lesion does NOT develop during follow-up.
Fig. 4
Fig. 4
Characteristics of dysplastic index lesions and dysplasia during follow-up.
See this image and copyright information in PMC

References

    1. Castaño-Mila C, Chaparro M, Gisbert J. Systematic review and meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39:645–659. - PubMed
    1. Bye W A, Nguyen T M, Parker C E et al.Strategies for detecting colon cancer in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2017;9:CD000279. - PMC - PubMed
    1. Imperatore M, Castiglione F, Testa A et al.Augmented endoscopy for surveillance of colonic inflammatory bowel disease: systematic review with network meta-analysis. J Crohns Colitis. 2019;13:714–724. - PubMed
    1. for the European Crohn’s and Colitis Organization [ECCO] . Magro F, Gionchetti P, Eliakim R. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649–670. - PubMed
    1. Rubin D T, Ananthakrishnan A N, Siegel C A et al.ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384–413. - PubMed